Familial hypercholesterolemia (FH) is a genetic disorder that leads to elevated plasma LDL-cholesterol levels and premature coronary heart disease (CHD). An understanding of the mutations responsible for FH and the effectiveness of statins in lowering the risk of CHD in FH patients has increased interest in genetic screening strategies to improve FH diagnosis. In this study, we aimed to evaluate the cost-effectiveness of such strategies.
The cost-effectiveness of genetic screening for familial hypercholesterolemia: a systematic review / Rosso, Annalisa; Pitini, Erica; D'Andrea, Elvira; Massimi, Azzurra; DE VITO, Corrado; Marzuillo, Carolina; Villari, Paolo. - In: ANNALI DI IGIENE MEDICINA PREVENTIVA E DI COMUNITÀ. - ISSN 1120-9135. - ELETTRONICO. - 29:5(2017), pp. 464-480. [10.7416/ai.2017.2178]
The cost-effectiveness of genetic screening for familial hypercholesterolemia: a systematic review
ROSSO, ANNALISA;PITINI, ERICA;D'ANDREA, ELVIRA;MASSIMI, AZZURRA;DE VITO, CORRADO;MARZUILLO, CAROLINA;VILLARI, Paolo
2017
Abstract
Familial hypercholesterolemia (FH) is a genetic disorder that leads to elevated plasma LDL-cholesterol levels and premature coronary heart disease (CHD). An understanding of the mutations responsible for FH and the effectiveness of statins in lowering the risk of CHD in FH patients has increased interest in genetic screening strategies to improve FH diagnosis. In this study, we aimed to evaluate the cost-effectiveness of such strategies.| File | Dimensione | Formato | |
|---|---|---|---|
|
Rosso_cost-effectiveness_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
166.8 kB
Formato
Adobe PDF
|
166.8 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
